Active, not recruitingPHASE1, PHASE2NCT05201248
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
Studying Cerebrotendinous xanthomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genmab
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Epcoritamab(drug)
- Enrollment
- 49 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2025
Study locations (18)
- The Fifth Medical Center of PLA General Hospital /ID# 230520, Beijing, Beijing Municipality, China
- Peking University Third Hospital /ID# 228138, Beijing, Beijing Municipality, China
- Fujian Medical University Union Hospital /ID# 231890, Fuzhou, Fujian, China
- Sun Yat-Sen University Cancer Center /ID# 228033, Guangzhou, Guangdong, China
- Guangdong Provincial People's Hospital /ID# 228028, Guangzhou, Guangdong, China
- Nanfang Hospital of Southern Medical University /ID# 227916, Guangzhou, Guangdong, China
- Henan Cancer Hospital /ID# 228772, Zhengzhou, Henan, China
- Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 231221, Wuhan, Hubei, China
- Hunan Cancer Hospital /ID# 231859, Changsha, Hunan, China
- The First Affiliated Hospital of Soochow University /ID# 228024, Suzhou, Jiangsu, China
- The Affiliated Hospital of Xuzhou Medical College /ID# 228774, Xuzhou, Jiangsu, China
- The First Affiliated Hospital of Nanchang University /ID# 228771, Nanchang, Jiangxi, China
- Jiangxi Provincial Cancer Hospital /ID# 231944, Nanchang, Jiangxi, China
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 227724, Shanghai, Shanghai Municipality, China
- West China Hospital, Sichuan University /ID# 231434, Chengdu, Sichuan, China
- +3 more locations on ClinicalTrials.gov
Collaborators
AbbVie
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05201248 on ClinicalTrials.govOther trials for Cerebrotendinous xanthomatosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07510802Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCBeijing Biotech
- RECRUITINGPHASE1NCT07162038Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell TransplantationNational Cancer Institute (NCI)
- RECRUITINGNANCT06790225Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)Esbjerg Hospital - University Hospital of Southern Denmark
- RECRUITINGPHASE2NCT05909059CAR T-cell Therapy in Patients With Renal DysfunctionNorthside Hospital, Inc.
- RECRUITINGPHASE2NCT06042569Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialCity of Hope Medical Center
- RECRUITINGPHASE1, PHASE2NCT06594640R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05748197A Study of ADCLEC.syn1 in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT05883852EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerFudan University